Zaveri Shruti, Sun Susie X, Zaghloul Tarek, Bevers Therese B, Albarracin Constance T, Patel Miral, Bedrosian Isabelle
Department of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ann Surg Oncol. 2025 May;32(5):3244-3251. doi: 10.1245/s10434-025-16933-6. Epub 2025 Jan 28.
Atypical ductal hyperplasia (ADH) is a benign proliferative breast lesion. Surgical excision of ADH is often recommended to rule out underlying malignant disease.
The aim of this study was to evaluate the trends in ADH upgrade rates over time and identify the impact of magnetic resonance imaging (MRI) use on upgrade rates.
Retrospective review of a prospectively maintained institutional database was used to identify women diagnosed with ADH by core needle biopsy between 2004 and 2022. Trends in ADH upgrade to in situ and invasive disease as well as clinicopathologic factors associated with upgrade were analyzed.
A total of 975 ADH cases were identified between 2004 and 2022. Of these, 361 (37.0%) met our multidisciplinary criteria for excision and thus met the inclusion criteria for this study. A total of 93 (25.8%) patients were found to have upgrade on final surgical pathology. When compared across quartiles of time, there were no significant changes in overall rates of upgrade over the study time period despite changes in diagnostic modalities. In women selectively referred for excision based on standardized imaging and pathology criteria, enhancement on preoperative MRI was not found to be significantly associated with increased rates of ADH upgrade.
While trends in diagnostic modality of ADH have changed over time, we found that rates of ADH upgrade have remained stable over time and are not associated with imaging modality, suggesting that enhancements in imaging technology have not improved our ability to preoperatively identify patients with a concurrent malignancy.
非典型导管增生(ADH)是一种良性乳腺增生性病变。通常建议对ADH进行手术切除,以排除潜在的恶性疾病。
本研究的目的是评估ADH升级率随时间的变化趋势,并确定磁共振成像(MRI)的使用对升级率的影响。
回顾性分析一个前瞻性维护的机构数据库,以确定2004年至2022年间通过粗针活检诊断为ADH的女性。分析ADH升级为原位癌和浸润性疾病的趋势以及与升级相关的临床病理因素。
2004年至2022年间共确定了975例ADH病例。其中,361例(37.0%)符合我们的多学科切除标准,因此符合本研究的纳入标准。共有93例(25.8%)患者在最终手术病理检查中发现升级。在按时间四分位数进行比较时,尽管诊断方式有所变化,但在研究时间段内总体升级率没有显著变化。在根据标准化成像和病理标准选择性转诊进行切除的女性中,术前MRI增强与ADH升级率增加无显著相关性。
虽然ADH的诊断方式随时间发生了变化,但我们发现ADH升级率随时间保持稳定,且与成像方式无关,这表明成像技术的进步并未提高我们术前识别并发恶性肿瘤患者的能力。